Skip to main content

Table 2 Modality of transbronchial lung biopsy

From: Diagnostic yield, safety, and impact of transbronchial lung biopsy in mechanically ventilated, critically ill patients: a retrospective study

Modality n (%)
No. of procedures 42
Type of procedure
 Forceps biopsy 39 (92.9)
 Cryobiopsy 3 (7.1)
 Fluoroscopy-guided biopsy 5 (11.9)
Place of procedure
 Intensive care unit 35 (83.3)
 Bronchoscopy unit 7 (16.7)
Airway access
 Endotracheal tube 27 (64.3)
 Tracheal cannula 13 (31.0)
 Rigid bronchoscope 2 (4.8)
Ventilator variables & respiratory indices
 P/F ratio (mmHg) 192.2 (± 89.8)
 FiO2 0.58 (± 0.22)
 IPAP (cmH2O) 27.2 (± 4.8)
 PEEP (cmH2O) 8.6 (± 2.9)
 LTCdyn (mL/cmH2O) 31.6 (± 15.4)
 Mechanical power (J/min) 26.2 (± 9.3)
Coagulation parameters
 aPTT (sec) 39 (± 12)
 INR 1.2 (± 0.2)
 Platelet count (per μL) 263 (± 139)
Anticoagulants/Antiaggregants
 No. of patients 21 (50.0)
 Thrombosis Prophylaxis 12 (28.6)
 Thrombosis Prophylaxis & ASS 7 (16.7)
 ASS 2 (4.8)
  1. Continuous variables are presented as mean values (± standard deviation); categorical variables are presented as number or number (%). Thrombosis Prophylaxis refers to Enoxaparin (≤ 40 mg/day s.c.) or unfractionated heparin (≤ 15.000 U/day s.c)
  2. Abbreviations: P/F ratio, ratio of partial pressure of oxygen to fraction of inspired oxygen, FiO2 fraction of inspired oxygen, IPAP inspiratory positive airway pressure, PEEP positive end-expiratory pressure, LTCdyn dynamic lung-thorax compliance, INR International Normalized Ratio, aPTT activated partial thromboplastin time, ASS acetylsalicylic acid (100 mg/day)